Oatly Group AB - ADR vs Vaxcyte Inc. Common Stock — how do they compare? Oatly Group AB - ADR trades at $11.1 (market cap $347.84M), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 30.2× Oatly Group AB - ADR's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oatly Group AB - ADR for 18 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| OTLY | PCVX | |
|---|---|---|
Market Cap | $347.84M | $10.51B |
Volume | 116,933 | 2,644,694 |
Sector | Consumer Staples | Health |
52-Week High | $15.91 | $73.82 |
52-Week Low | $8.03 | $40.32 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $852.26M | $9.14B |
Signals from Pluang's Aura AI — not financial advice
OTLY trades at $11.15, up 4.5% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth to $862M in 2025 and narrowing losses, though it remains unprofitable with negative cash flow. Recent Q2 2026 results beat expectations and management raised full-year revenue guidance, driving positive sentiment.
While OTLY demonstrates operational progress with margin improvement and revenue acceleration, significant risks remain including persistent losses, high debt levels, and negative cash flow. Analyst consensus is mixed with 44% buy ratings but a modest $12.28 price target suggesting limited upside from current levels amid ongoing profitability challenges.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →